JPMorgan Chase & Co.
Filed with the SEC on · accession 0000019617-26-000402
CYCN filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 10, 2026. JPMorgan Chase & Co. filed a Schedule 13G reporting beneficial ownership of 2,687,914 shares, or 5.9%, of Korsana Biosciences, Inc. (formerly Cyclerion Therapeutics).
JPMorgan Chase & Co. filed a Schedule 13G reporting beneficial ownership of 2,687,914 shares, or 5.9%, of Korsana Biosciences, Inc. (formerly Cyclerion Therapeutics). The filing is a passive investment disclosure under Rule 13d-1(b).
✦ Ask GOAX AI about this filing — what it means for CYCN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CYCN?
Click hereCYCN filed a SCHEDULE 13G (SEC filing). JPMorgan Chase & Co. filed a Schedule 13G reporting beneficial ownership of 2,687,914 shares, or 5.9%, of Korsana Biosciences, Inc. (formerly Cyclerion Therapeutics). The filing is a passive investment disclosure under Rule 13d-1(b).
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
Get alerts when CYCN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days